Artiva Biotherapeutics (ARTV) Total Current Liabilities (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Total Current Liabilities data on file, last reported at $10.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 10.85% year-over-year to $10.9 million in Q1 2026; TTM through Mar 2026 was $10.9 million, a 10.85% decrease from a year earlier, with the FY2025 full-year figure at $13.1 million, up 6.81% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $10.9 million, down from $13.1 million in the prior quarter.
• Over the last five years, Total Current Liabilities for ARTV reached as high as $13.3 million in Q3 2024 and fell as low as $10.8 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $11.9 million across 4 years, with a median of $12.2 million in 2025.
• On a YoY basis, Total Current Liabilities climbed as much as 6.81% in 2025 and fell as far as 16.35% in 2025.
• Year by year, Total Current Liabilities stood at $12.2 million in 2023, then gained by 0.21% to $12.3 million in 2024, then climbed by 6.81% to $13.1 million in 2025, then declined by 16.86% to $10.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $10.9 million in Q1 2026, $13.1 million in Q4 2025, and $11.1 million in Q3 2025.